SAB Biotherapeutics SAB-142 receives Breakthrough T1D grant
Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 for new-onset type 1 diabetes patients.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day